Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evolocumab for Coronary Microvascular Dysfunction (MICROPROTECT)
NCT04338165Phase 2Unknown
- Sponsor
- CHU Grenoble Alpes
- Start
- Jan 2021
- Primary completion
- Nov 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of evolocumab in Coronary Microvascular Dysfunction (CMD), atherosclerotic cardiovascular disease (ASCVD), sponsored by CHU Grenoble Alpes. Status: unknown.
02
Drugs
evolocumab
03
Conditions
Coronary Microvascular Dysfunction (CMD)atherosclerotic cardiovascular disease (ASCVD)
Beyond the preview
Go deeper on NCT04338165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04338165.